Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants

Aminata Kane, Catherine Uzan, Annie Rey, Sebastien Gouy, Sophie Camatte, Patricia Pautier, Catherine Lhommé, Christrine Haie-Meder, Pierre Duvillard, Philippe Morice

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    60 Citations (Scopus)

    Résumé

    Background. The objective of this study was to determine prognostic factors in a large series of patients with stage II or III serous low malignant potential ovarian tumor (LMPOT) and peritoneal implants. Methods. Patients with a serous LMPOT and peritoneal implants treated at or referred to our institution were retrospectively reviewed. The slides of ovarian tumors and peritoneal implants were reviewed by the same pathologist. Results. From 1969 to 2006, 168 patients were reviewed, 21 of whom had invasive implants. Tumors exhibited a micropapillary pattern in 56 patients. Adjuvant treatment had been administered to 61 patients. The median duration of follow-up was 57 months (range, 1-437). Forty-four patients had relapsed and 10 patients had died. The 5-year overall survival rate was 98%. Among patients with noninvasive and invasive implants, 8% and 10%, respectively, had relapsed at 5 years in the form of invasive disease (p = .08). In a multivariate analysis, the use of conservative treatment was the only prognostic factor. Interpretation. The prognosis of serous LMPOT with peritoneal implants remains good. The strongest prognostic factor in patients with an advanced-stage borderline tumor is the use of conservative surgery. In this series, a micropapillary pattern and implant subtype (invasive versus noninvasive) were not prognostic factors.

    langue originaleAnglais
    Pages (de - à)591-600
    Nombre de pages10
    journalOncologist
    Volume14
    Numéro de publication6
    Les DOIs
    étatPublié - 1 juin 2009

    Contient cette citation